Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Millennium: The Takeda Oncology Company today announced that Phase II results of a clinical trial examining VELCADE (bortezomib) in patients with previously untreated aggressive lymphoma were published in the Journal of Clinical Oncology.

5 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Study reveals how MMSET gene enables disease-causing mutations to occur

For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place.

3 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2010.

27 Jan 2011

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuticals, for a combination of cash and contingent payments.

26 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Senesco files SNS01-T IND for treatment of multiple myeloma

Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.

24 Jan 2011

Scientist receives RO1 research grant to improve blood, marrow transplantation in myeloma patients

Thea Friedman, M.D., associate scientist and director of oncology basic research at the John Theurer Cancer Center at Hackensack University Medical Center was recently awarded a National Cancer Institutes of Health-National Cancer Institute RO1 research grant to improve allogeneic blood and marrow transplantation for multiple myeloma patients.

21 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

20% of cancer survivors experience chronic pain: Study

Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics' new gene expression profile test for Multiple Myeloma to community-based hematologists/medical oncologists nationwide.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Study reveals how MMSET gene enables disease-causing mutations to occur

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Empire State Building, NYRR partner with MMRF for new myeloma drugs

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

Ligand announces acquisition of CyDex Pharmaceuticals

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Senesco files SNS01-T IND for treatment of multiple myeloma

Scientist receives RO1 research grant to improve blood, marrow transplantation in myeloma patients

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

20% of cancer survivors experience chronic pain: Study

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Study supports use of telomerase inhibitors for treatment of childhood cancers

MMRF awards $3 million under 2010 Biotech Investment Awards program

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Signal Genetics, Caris Life Sciences announce new agreement to commercialize MyPRS tool

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in